UCB is a global biopharmaceutical company headquartered in Brussels. In 2006 it had global revenues of 2.5 billion euro, employed approximately 8,400 people and operated in 40 countries. 
On its website it states that its primary focus is on products in "the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology." 
Discover Which Corporations are the Biggest Violators of Environmental, Health and Safety Laws in the United States
Violation Tracker is the first national search engine on corporate misconduct covering environmental, health, and safety cases initiated by 13 federal regulatory agencies. Violation Tracker is produced by the Corporate Research Project of Good Jobs First. Click here to access Violation Tracker.
Funding 'Patient Groups'
In 2006, ECB contributed CHF 30,000 to the European Patients' Forum, a group overwhelmingly funded by the drug industry.  One of its priority activities has been to support proposals to overturn the European Union ban on direct-to-consumer advertising. (See Direct-to-consumer advertising: The Campaign To Overturn Europe's Ban for the details of the history of the debate in Europe).
Other SourceWatch Resources
- Drug industry
- Direct-to-consumer advertising
- Direct-to-consumer advertising: The Campaign To Overturn Europe's Ban
Alle de la Recherche, 60